Brevan Howard Capital Management’s Sage Therapeutics SAGE Stock Holding History

Brevan Howard Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-131,987	Closed	-$1.05M	–	1992
2025 Q1	$1.05M	Buy	+131,987	New	+$966K	0.01%	481
2024 Q4	–	Sell	-16,847	Closed	-$122K	–	1381
2024 Q3	$122K	Sell	16,847 -26,569	-61%	-$243K	﹤0.01%	1058
2024 Q2	$471K	Buy	43,416 +23,515	+118%	+$301K	﹤0.01%	629
2024 Q1	$373K	Sell	19,901 -1,366	-6%	-$31.5K	﹤0.01%	568
2023 Q4	$461K	Buy	+21,267	New	+$421K	0.01%	518

Other funds holding SAGE

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Brevan Howard Capital Management's SAGE Position: Q2 2025 in Review

Brevan Howard Capital Management sold out of Sage Therapeutics (SAGE) in Q2 2025, closing a stake of 131,987 shares — an estimated $1.05M sold.

Brevan Howard Capital Management first reported a position in SAGE in Q4 2023 and held it in 5 quarters. The position peaked at $1.05M in Q1 2025. 192 funds tracked by Wall St. Rank hold SAGE as of Q2 2025.

Brevan Howard Capital Management reported no remaining Sage Therapeutics position as of Q2 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 131,987 Sage Therapeutics shares in Q2 2025, an estimated $1.05M.
Brevan Howard Capital Management first reported a position in Sage Therapeutics in Q4 2023 and held it in 5 quarters.
Brevan Howard Capital Management's Sage Therapeutics position peaked at $1.05M in Q1 2025.
192 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2025.

Based on Brevan Howard Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.